A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

Trial Identifier: EFC15299
Sponsor: Genzyme, a Sanofi Company
Start Date: June 2020
Primary Completion Date: December 2024
Study Completion Date: December 2024
Condition: Tay-Sachs Disease; Sandhoff disease

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
ARGENTINA, Buenos Aires Pilar, Buenos Aires, ARGENTINA, B1629ODT
ARGENTINA, Córdoba Córdoba, ARGENTINA, X5004FHP
BRAZIL, Rio Grande do Sul Porto Alegre, Rio Grande do Sul, BRAZIL, 90035 003
CZECHIA Praha 2, CZECHIA, 12808
FRANCE PARIS, FRANCE, 75013
GERMANY Gießen, GERMANY, 35390
Italy, Milano Milano, Italy, 20133
JAPAN, Akita Akita-shi, Akita, JAPAN, 010-1495
JAPAN, Miyagi Sendai-shi, Miyagi, JAPAN, 983-8512
PORTUGAL Lisboa, PORTUGAL, 1649-035
RUSSIAN FEDERATION Moscow, RUSSIAN FEDERATION, 125367
SPAIN, Barcelona [Barcelona] Hospitalet de Llobregat, Barcelona [Barcelona], SPAIN, 08907
SPAIN, Catalunya [Cataluña] Esplugues de Llobregat, Catalunya [Cataluña], SPAIN, 08950
SPAIN, Galicia [Galicia] Santiago de Compostela, Galicia [Galicia], SPAIN, 15706
Turkey Ankara, Turkey, 06500
United Kingdom, Manchester Manchester, United Kingdom, M13 9WL
UNITED KINGDOM, Cambridgeshire Cambridge, Cambridgeshire, UNITED KINGDOM, CB2 OQQ
UNITED KINGDOM, Not Known Salford, Not Known, UNITED KINGDOM, M6 8HD
UNITED STATES, California Los Angeles, California, UNITED STATES, 90095
UNITED STATES, Georgia Atlanta, Georgia, UNITED STATES, 30322
UNITED STATES, Maryland Bethesda, Maryland, UNITED STATES, 20892
UNITED STATES, Massachusetts Boston, Massachusetts, UNITED STATES, 02114
UNITED STATES, New York New York, UNITED STATES, 10016